Medrobotics gets expanded CE mark nod for its robot-assisted surgical device

The European Union has given its CE mark approval to Medrobotics’ Flex robot-assisted surgery system, expanding the device’s indication to include colorectal procedures. 

The company, which is based in Raynham, MA, touts itself as the first in its field to offer minimally invasive and steerable robotic products for colorectal uses.

“CE Mark for colorectal procedures is significant since it expands the number of patients who can be treated with the Flex robotic system and provides a true platform technology that multiple hospital departments can use,” Samuel Straface, Medrobotics’ CEO, said in a statement. “When combined with the unrivaled mobility of the system, European otolaryngology and colorectal surgeons can now perform minimally invasive surgery through the body’s natural orifices, offering the potential for truly scarless surgeries.”

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

Earlier this year, the Flex system won Best-in-Show honors at the Medical Design Excellence Awards. The robot-assisted surgical platform is designed to be affordable, easy-to-use and highly mobile for hospitals and surgeons when performing minimally invasive treatments, the company said.

In November last year, Medrobotics raised $25 million just months after gaining FDA 510(k) clearance for transoral procedures.

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.